Skip to Main Content

INFORMATION FOR

Stuart Alan Weinzimer, MD

Professor; Interim Section Chief, Pediatric Endocrinology & Diabetes

Research Summary

My research focuses on the application of new technologies to the treatment of diabetes. As part of my collaborations within the Diabetes Research in Children Network (DirecNet) and the Juvenile Diabetes Research Foundation Artificial Pancreas Project, I have been studying the safety, accuracy, and effectiveness of continuous glucose sensors to improve diabetes therapy, as well as investigating basic physiological questions of hypoglycemia counter-regulation. My main focus now is on the development of a so-called "artificial pancreas", in which an insulin pump automatically delivers the appropriate amount of insulin at any given time based upon receiving information from glucose sensor devices. I am also collaborating with several other pediatric endocrinologists and neuroimaging specialists to deterimne the effects of childhood diabetes on brain growth and function in children diagnosed with diabetes at a young age.

Specialized Terms: Insulin pump therapy; Continuous glucose sensors; Artificial pancreas

Coauthors

Research Interests

Diabetes Mellitus, Type 1; Endocrinology; Insulin; Insulin Infusion Systems; Pediatrics; Pancreas, Artificial

Selected Publications

  • “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetesHughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. DOI: 10.1016/j.jcte.2022.100310.
  • 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 DiabetesWILCOX A, MENCHER S, NALLY L, WEINZIMER S. 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes Diabetes 2022, 71 DOI: 10.2337/db22-1025-p.
  • 619-P: Understanding Parental Influences on T1D Incorporation in Adolescents and Young AdultsCOMMISSARIAT P, VOLKENING L, WEINZIMER S, DASSAU E, LAFFEL L. 619-P: Understanding Parental Influences on T1D Incorporation in Adolescents and Young Adults Diabetes 2022, 71 DOI: 10.2337/db22-619-p.
  • 49-LB: Navigating Barriers to Affording and Obtaining Diabetes TreatmentWILCOX A, KERANDI L, LIPSKA K, WEINZIMER S, NALLY L. 49-LB: Navigating Barriers to Affording and Obtaining Diabetes Treatment Diabetes 2021, 70 DOI: 10.2337/db21-49-lb.
  • PR3 Identifying Preferences for Closed-Loop Insulin Systems Among Children with Type 1 Diabetes and Their Parents: A Discrete Choice ExperimentKelley M, Wadwa P, Buckingham B, Thankamony A, Campbell F, Weinzimer S, Mauras N, DiMeglio L, Denvir L, Davis N, Ghatak A, Besser R, Fox D. PR3 Identifying Preferences for Closed-Loop Insulin Systems Among Children with Type 1 Diabetes and Their Parents: A Discrete Choice Experiment Value In Health 2021, 24: s196-s197. DOI: 10.1016/j.jval.2021.04.983.
  • 214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised TrialFUCHS J, BOUGHTON C, ALLEN J, WILINSKA M, TAUSCHMANN M, DENVIR L, THANKAMONY A, CAMPBELL F, WADWA R, BUCKINGHAM B, DAVIS N, DIMEGLIO L, MAURAS N, BESSER R, GHATAK A, WEINZIMER S, HOOD K, FOX D, KANAPKA L, KOLLMAN C, SIBAYAN J, BECK R, HOVORKA R. 214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised Trial Diabetes 2021, 70 DOI: 10.2337/db21-214-or.
  • 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1DHUGHES A, CHAPMAN K, BISPHAM J, HEYDARIAN N, DIMSITS J, WEINZIMER S, WOLF W. 51-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D Diabetes 2021, 70 DOI: 10.2337/db21-51-lb.
  • Automated Insulin DeliveryWeinzimer S, Carria L, Van Name M. Automated Insulin Delivery 2021, 75-85. DOI: 10.1007/978-3-030-64133-7_8.
  • 1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) SystemCOMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1298-P: “I Would Rather Bolus”: Youth and Parents Prefer Manual Bolusing to Carbohydrate Limitations in a Fully Automated Artificial Pancreas (AP) System Diabetes 2020, 69 DOI: 10.2337/db20-1298-p.
  • 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1DHUGHES A, BISPHAM J, FULLER L, WOLF W, FITCH S, WEINZIMER S. 8-LB: Emotional Impact of Hypoglycemia and Use of Glucagon: Perspectives of People with T1D and Caregivers of Minors with T1D Diabetes 2020, 69 DOI: 10.2337/db20-8-lb.
  • 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and ParentsROETHKE L, COMMISSARIAT P, FINNEGAN J, VOLKENING L, BUTLER D, DASSAU E, WEINZIMER S, LAFFEL L. 998-P: Alerts from an Ideal Artificial Pancreas (AP) System: Preferences of Young Persons with Type 1 Diabetes (T1D) and Parents Diabetes 2020, 69 DOI: 10.2337/db20-998-p.
  • Longitudinal assessment of hippocampus structure in children with type 1 diabetesLC F, AL R, PK M, N M, SA W, T A, MJ T, NH W. Longitudinal assessment of hippocampus structure in children with type 1 diabetes 2019 DOI: 10.1530/ey.16.10.13.
  • 1346-P: Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes: Persistent Effects on IQ and VocabularyWEINZIMER S, AMBROSINO J, CATO A, JO B, ENGLERT K, WHITE N, ARBELAEZ A, HERSHEY T, FOX L, TSALIKIAN E, TANSEY M, BUCKINGHAM B, AYE T, WILSON D, TAMBORLANE W, REISS A, MAURAS N. 1346-P: Longitudinal Evaluation of Cognitive Functioning in Young Children with Type 1 Diabetes: Persistent Effects on IQ and Vocabulary Diabetes 2019, 68 DOI: 10.2337/db19-1346-p.
  • 1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 DiabetesFOLAND-ROSS L, BUCKINGHAM B, MAURAS N, ARBELAEZ A, WHITE N, AYE T, WILSON D, TAMBORLANE W, WEINZIMER S, TSALIKIAN E, TANSEY M, CATO A, HERSHEY T, FOX L, TONG G, ENGLERT K, MAZAIKA P, REISS A. 1382-P: Impaired Default Mode Network Suppression and Compensatory Hyperactivation in Children with Type 1 Diabetes Diabetes 2019, 68 DOI: 10.2337/db19-1382-p.
  • 209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet)ARBELAEZ A, O’DONOGHUE S, MAURAS N, BUCKINGHAM B, WHITE N, WEINZIMER S, AYE T, TSALIKIAN E, WILSON D, TAMBORLANE W, TANSEY M, CATO A, HERSHEY T, FOX L, ENGLERT K, REISS A. 209-OR: ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet) Diabetes 2019, 68 DOI: 10.2337/db19-209-or.
  • 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1DDANNE T, PETTUS J, GIACCARI A, CARIOU B, RODBARD H, WEINZIMER S, BONNEMAIRE M, SAWHNEY S, WANG S, CASTRO R, GARG S. 1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D Diabetes 2019, 68 DOI: 10.2337/db19-1220-p.
  • 1361-P: Features to Increase Glycemic Benefits in an Ideal Artificial Pancreas (AP): Perspectives of Young Persons with Type 1 Diabetes (T1D)COMMISSARIAT P, ROETHKE L, FINNEGAN J, VOLKENING L, MCGILL D, DASSAU E, WEINZIMER S, LAFFEL L. 1361-P: Features to Increase Glycemic Benefits in an Ideal Artificial Pancreas (AP): Perspectives of Young Persons with Type 1 Diabetes (T1D) Diabetes 2019, 68 DOI: 10.2337/db19-1361-p.
  • 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D)COMMISSARIAT P, ROETHKE L, VOLKENING L, BUTLER D, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 816-P: Pediatric Preferences for an Ideal Artificial Pancreas (AP): Unique Features to Reduce Self-Care Burdens of Type 1 Diabetes (T1D) Diabetes 2019, 68 DOI: 10.2337/db19-816-p.
  • 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) SurveyCOMMISSARIAT P, VOLKENING L, ROETHKE L, GUO Z, FINNEGAN J, DASSAU E, WEINZIMER S, LAFFEL L. 817-P: Validation of a New Survey to Assess Incorporation of Type 1 Diabetes (T1D) into Identity of Young Persons: Accepting Diabetes and Personal Treatment (ADAPT) Survey Diabetes 2019, 68 DOI: 10.2337/db19-817-p.
  • Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1DPETTUS J, WEINZIMER S, MCCRIMMON R, AMPUDIA BLASCO F, STEWART J, STRUMPH P, OLIVEIRA J, LAPUERTA P, CASTRO R. Sotagliflozin in Combination with Optimized Insulin Therapy Reduced HbA1c Levels with a Decreased Daily Insulin Requirement after 52 Weeks in Adults with T1D Diabetes 2018, 67 DOI: 10.2337/db18-5-lb.
  • Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG StudyPINSKER J, LI Z, BUCKINGHAM B, FORLENZA G, CENGIZ E, CHURCH M, EKHLASPOUR L, PAUL WADWA R, WEINZIMER S, ANDRE C, MARCAL T, JOST E, CARRIA L, WOODALL W, DOKKEN B, SWANSON V, LUM J, KOLLMAN C, BECK R. Exceptional Usability of Tandem t:slim X2 with Basal-IQ Predictive Low-Glucose Suspend (PLGS)—The PROLOG Study Diabetes 2018, 67 DOI: 10.2337/db18-86-lb.
  • Safety and Health Outcomes of a Physical Activity Program for Adolescents with Type 1 DiabetesAsh G, Joiner K, Savoye M, Baker J, Gerosa J, Kleck E, Patel N, Stults-Kolehmainen M, Weinzimer S, Grey M. Safety and Health Outcomes of a Physical Activity Program for Adolescents with Type 1 Diabetes Medicine & Science In Sports & Exercise 2018, 50: 695. DOI: 10.1249/01.mss.0000538288.29524.c4.
  • 014–Pivotal Trial of a Hybrid-Closed Loop System in Type 1 DabetesBurkett L, Lee S, Shin J, Kaufman F, Buckingham B, Slover R, Weinzimer S. 014–Pivotal Trial of a Hybrid-Closed Loop System in Type 1 Dabetes Journal Of Pediatric Nursing 2017, 34: 106. DOI: 10.1016/j.pedn.2017.02.023.
  • Abstract #249: The Variability in Nighttime Insulin Delivery and Glucose Levels with a Hybrid Closed-Loop System in a Pivotal TrialLee S, Bailey T, Brazg R, Slover R, Ilany J, Bode B, Garg S, Buckingham B, Anderson S, Weinzimer S, Bergenstal R, Tamborlane W, Roy A, Cordero T, Huang S, Shin J, Kaufman F. Abstract #249: The Variability in Nighttime Insulin Delivery and Glucose Levels with a Hybrid Closed-Loop System in a Pivotal Trial Endocrine Practice 2017, 23: 56-57. DOI: 10.1016/s1530-891x(20)44369-1.
  • Future Drug Treatments for Type 1 DiabetesSherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes 2016, 985-999. DOI: 10.1002/9781118924853.ch66.
  • CHAPTER 19 Diabetes mellitusSperling M, Tamborlane W, Battelino T, Weinzimer S, Phillip M. CHAPTER 19 Diabetes mellitus 2014, 846-900.e1. DOI: 10.1016/b978-1-4557-4858-7.00028-7.
  • The Impact of Insulin Pharmacokinetics and Pharmacodynamics on the Closed-loop Artificial PancreasLee J, Dassau E, Zisser H, Tamborlane W, Weinzimer S, Doyle F. The Impact of Insulin Pharmacokinetics and Pharmacodynamics on the Closed-loop Artificial Pancreas 2013, 127-132. DOI: 10.1109/cdc.2013.6759870.
  • Interstitial fluid glucose time-lag correction for real-time continuous glucose monitoringKeenan D, Mastrototaro J, Weinzimer S, Steil G. Interstitial fluid glucose time-lag correction for real-time continuous glucose monitoring Biomedical Signal Processing And Control 2013, 8: 81-89. DOI: 10.1016/j.bspc.2012.05.007.
  • CHAPTER 10 Diabetes MellitusSPERLING M, WEINZIMER S, TAMBORLANE W. CHAPTER 10 Diabetes Mellitus 2008, 374-421. DOI: 10.1016/b978-141604090-3.50015-6.
  • Hypoglycemia in childhood type 1 diabetes mellitus: Understanding and managing the dark side of intensive insulin therapyTamborlane W, Swan K, Weinzimer S. Hypoglycemia in childhood type 1 diabetes mellitus: Understanding and managing the dark side of intensive insulin therapy Insulin 2007, 2: 157-165. DOI: 10.1016/s1557-0843(07)80059-5.
  • Should continuous glucose monitors be used routinely in pediatric patients?Weinzimer S, Wilson D. Should continuous glucose monitors be used routinely in pediatric patients? Family Practice News 2006, 36: 8. DOI: 10.1016/s0300-7073(06)73924-x.
  • Should continuous glucose monitors be used routinely in adolescent patients?WEINZIMER S, WILSON D. Should continuous glucose monitors be used routinely in adolescent patients? Internal Medicine News 2006, 39: 9. DOI: 10.1016/s1097-8690(06)74256-1.
  • Chapter 37 Diabetes Mellitus in Children and AdolescentsWeinzimer S, Tamborlane W. Chapter 37 Diabetes Mellitus in Children and Adolescents 2006, 505-521. DOI: 10.1016/b978-1-4160-0273-4.50042-4.
  • Analysis: How to Inspect When She's Expecting: Use of Continuous Glucose Monitoring in Diabetes During PregnancyWeinzimer S. Analysis: How to Inspect When She's Expecting: Use of Continuous Glucose Monitoring in Diabetes During Pregnancy Diabetes Technology & Therapeutics 2005, 7: 707-709. DOI: 10.1089/dia.2005.7.707.
  • CHAPTER 1 Type 1 Diabetes Mellitus in ChildrenWEINZIMER S, MAGGE S. CHAPTER 1 Type 1 Diabetes Mellitus in Children 2005, 3-18. DOI: 10.1016/b978-0-323-01825-8.50030-2.
  • CHAPTER 2 Type 2 Diabetes Mellitus in Children and AdolescentsHALE D, WEINZIMER S. CHAPTER 2 Type 2 Diabetes Mellitus in Children and Adolescents 2005, 19-35. DOI: 10.1016/b978-0-323-01825-8.50031-4.
  • Diabetes Mellitus in Children and AdolescentsWeinzimer S, Tamborlane W. Diabetes Mellitus in Children and Adolescents 2004 DOI: 10.1002/0470862092.d0809.
  • Management of Endocrine Dysfunction Following Brain Tumor TreatmentWeinzimer S, Moshang Jr. T. Management of Endocrine Dysfunction Following Brain Tumor Treatment 2003, 0: 173-188. DOI: 10.1385/1-59259-336-4:173.
  • Biological significance of insulin-like growth factor binding proteinsWeinzimer S, Cohen P. Biological significance of insulin-like growth factor binding proteins 2002, 2: 37-65. DOI: 10.1016/s1567-7443(02)80007-2.
  • Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding ProteinWeinzimer S, Gibson T, Collett-Solberg P, Khare A, Liu B, Cohen P. Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding Protein The Journal Of Clinical Endocrinology & Metabolism 2001, 86: 1806-1813. DOI: 10.1210/jcem.86.4.7380.
  • Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3Mannhardt B, Weinzimer S, Wagner M, Fiedler M, Cohen P, Jansen-Dürr P, Zwerschke W. Human Papillomavirus Type 16 E7 Oncoprotein Binds and Inactivates Growth-Inhibitory Insulin-Like Growth Factor Binding Protein 3 Molecular And Cellular Biology 2000, 20: 6483-6495. DOI: 10.1128/.20.17.6483-6495.2000.
  • The IGF Axis in the Male Reproductive SystemWeinzimer S, Cohen P. The IGF Axis in the Male Reproductive System 1999, 407-423. DOI: 10.1007/978-1-59259-712-3_18.
  • ReplyWeinzimer S, Stanley C. Reply The Journal Of Pediatrics 1998, 133: 169. DOI: 10.1016/s0022-3476(98)70207-0.
  • Variability of Low IGF-I and IGFBP-3 Levels in Predicting Growth Hormone Deficiency in Children with Brain Tumors † 497Weinzimer S, Ferry R, Homan S, Moshang T. Variability of Low IGF-I and IGFBP-3 Levels in Predicting Growth Hormone Deficiency in Children with Brain Tumors † 497 Pediatric Research 1998, 43: 87-87. DOI: 10.1203/00006450-199804001-00518.
  • USE OF A SENSITIVE ASSAY TO DOCUMENT ELEVATED INSULIN LEVELS IN CONGENITAL HYPERINSULINISM. † 575Satin-Smith M, Katz L, Drott H, Collett-Solberg P, Weinzimer S, Thornton P, Baker L, Stanley C. USE OF A SENSITIVE ASSAY TO DOCUMENT ELEVATED INSULIN LEVELS IN CONGENITAL HYPERINSULINISM. † 575 Pediatric Research 1996, 39: 98-98. DOI: 10.1203/00006450-199604001-00596.
  • GROWTH HORMONE DEFICIENCY IN THE 22Q11 DELETION SYNDROME: A REPORT OF THREE CASES. † 881Weinzimer S, McDonald-McGinn D, Zackai E, Moshang T. GROWTH HORMONE DEFICIENCY IN THE 22Q11 DELETION SYNDROME: A REPORT OF THREE CASES. † 881 Pediatric Research 1996, 39: 149-149. DOI: 10.1203/00006450-199604001-00903.
  • HYPERINSULINISM AND HYPERAMMONEMIA: A DISTINCT GENETIC SYNDROME.† 882Weinzimer S, Yudkoff M, Thornton P, Stanley C. HYPERINSULINISM AND HYPERAMMONEMIA: A DISTINCT GENETIC SYNDROME.† 882 Pediatric Research 1996, 39: 149-149. DOI: 10.1203/00006450-199604001-00904.

Clinical Trials

ConditionsStudy Title
Diabetes Mellitus - Type 1Virtual Physical Activity for Type 1 Diabetes
Diabetes Mellitus - Type 1; Diabetes Mellitus - Type 2FreeStyle Libre 2 Flash Glucose Monitoring System Intervention Phase Study for Pediatric Patients
Diseases of the Blood; COVID-19 Inpatient; COVID-19 OutpatientMechanisms for restoration of hypoglycemia awareness
Diabetes Mellitus - Type 1; Diseases of the Endocrine System; Diseases of the Nervous SystemImpact of Hypoglycemia on Brain Ketone and Neurotransmitter Metabolism in Type 1 DM
Children's Health; Diabetes Mellitus - Type 1; Diseases of the Endocrine SystemPathway to Prevention Study